Thomas Feldthus (born 1960) is an entrepreneur with extensive management experience within the life science industry.
Feldthus is a co-founder of Saniona. Prior to joining Saniona as CEO in April 2022, he most recently served for the company as vVD and CFO from 2012 to March 2020. Apart from Saniona, he is a co-founder of Scandion Oncology A/S, Initiator Pharma A/S, Symphogen A/S, Ataxion Inc. and Leukotech ApS. Previously, he served as CFO of Symphogen A/S, Investment Associate at Novo A/S and Corporate Development Manager at Novo Nordisk A/S.
Feldthus serves as Chairman of the board of directors for Rehaler ApS and as a member of the board of directors for Synklino A/S and ResoTher Pharma ApS.
Feldthus earned his M.Sc. in Management and Economics from the University of London, Fellow of the London Business School Sloan Program from London Business School (LBS), Graduate Diploma in Business Administration (Marketing Management) from Copenhagen Business School (CBS), and M.Sc. in Engineering from the Technical University of Denmark (DTU).
Feldthus holds 1,661,928 warrants in the warrant program 2022 and 965,000 shares.